Načítá se...

Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Seban, Romain-David, Robert, Charlotte, Dercle, Laurent, Yeh, Randy, Dunant, Ariane, Reuze, Sylvain, Schernberg, Antoine, Sun, Roger, Mignot, Fabien, Terroir, Marie, Schlumberger, Martin, Haie-Meder, Christine, Chargari, Cyrus, Deutsch, Eric
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492982/
https://ncbi.nlm.nih.gov/pubmed/31069132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1574197
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!